Prakt. lékáren. 2012; 8(6): 275-278

Pharmaceutical care of oncologic patients - adverse effects II.

Jindřiška Voláková
Nemocniční lékárna, FN Hradec Králové

In addition to the gastrointestinal adverse effects which were discussed in the first part of this article, oncologic patients suffer from

dermal and hematologic adverse effects and persisting fatigue, too.

Although the therapy of these adverse effects is mainly at the hands of the physician, the pharmacist can give adice and help the patient

especially by common information about the symptoms of adverse effects and explanation of their reasons or by reccomendation of

factual regime precautions and OTC drugs which can reduce the adverse effects or prevent them.

Keywords: adverse effects, oncologic therapy, oncologic patient, pharmaceutical care

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Voláková J. Pharmaceutical care of oncologic patients - adverse effects II. Praktické lékárenství. 2012;8(6):275-278.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adam Z, Vorlíček J, Koptíková J. Obecná onkologie a podpůrná léčba. Grada Publishing 2003: 346-354.
    2. Vorlíček J, Adam Z, Šmardová L, Vorlíčková H. Chemoterapie a Vy, rady pro nemocné léčené chemoterapií 2007: 19-20.
    3. Gatzemeier U, Pawel J, Vynnychenko I, Zatloukal P, de Marinis F, Eberhardt W, Paz-Ares L, Schumacher K, Goddemeier T, O´Byrne K, Prker R. First cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy. The Lancet Oncology 2011; 12: 30-37. Go to original source... Go to PubMed...
    4. Vyzula R, a kol. Zásady cytostatické léčby maligních onkologických onemocnění - Doporučení pro léčbu kožních změn v důsledku terapie inhibitory EGFR (pro rok 2011). Masarykův onkologický ústav 2011: 171-172 http://www.linkos.cz/informace-pro-praxi/zasady-cytostaticke-lecby/31-doporuceni-pro-lecbu-koznich-zmen-v-dusledku-terapie-inhibitory-egfr-pro-rok-2011/.
    5. Krajsová I. Kožní projevy cílené léčby nádorů. Remedia 2006; 4: 416-420.
    6. Bednaříková D, Kocák I. Hand-foot syndrom po podání inhibitorů tyrozinkinázové aktivity. Klinická onkologie 2010; 23: 300-305. Go to PubMed...
    7. Vyzula R, a kol. Zásady cytostatické léčby maligních onkologických onemocnění - Doporučení pro léčbu hematologických toxicit. Masarykův onkologický ústav 2011: 157-163 http://www.linkos.cz/informace-pro-praxi/zasady-cytostaticke-lecby/29-doporuceni-pro-lecbu-hematologickych-toxicit/.
    8. Rath T. Iron and erythropoiesis-stimulating agents in anaemia. European Journal of oncology pharmacy 2010; 3: 20-21.
    9. Vorlíček J, Adam Z, Šmardová L, Vorlíčková H. Chemoterapie a Vy, rady pro nemocné léčené chemoterapií 2007: 14-15.
    10. Adam Z, Vorlíček J, Koptíková J. Obecná onkologie a podpůrná léčba. Grada Publishing 2003: 346-354.
    11. Adam Z, Vorlíček J, Koptíková J. Obecná onkologie a podpůrná léčba. Grada Publishing 2003: 705-708.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.